Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 17

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 17
---
 (including the completion of our pivotal trial) and preparation of the PMA submission for GelrinC; |

| ● | approximately $1.0 million for operations (manufacturing, regulatory affairs and patents); |

| ● | approximately $0.5 million for research and development activities; |

| ● | approximately $0.5 million for EU marketing development (Medical Device Regulation qualification and scaleup); |

| ● | approximately                                                                                                                 
 $1.1 million for the repayment of the Bridge Loan, the loans under the 2024 Loan Agreements, the 2025 Loan Agreements and the 
 December 2024 Loan Agreement (each, as defined below) and accrued interest and applicable risk premium;                       |

| ● | $0.25 million to be paid to the                                                                                                                      
 Chairman of our board of directors in consideration of his services to the Company since 2019, for which he has not received compensation, which was 
 approved by our shareholders on March 20, 2025; and                                                                                                  |

| ● | the remainder for working capital and general corporate purposes and possible future acquisitions. |

| The amounts and schedule of our actual expenditures will depend on multiple factors. As a result, our management will have broad discretion in the application of the net proceeds of this offering. For additional information regarding the repayment of the Bridge Loan, see “Certain Relationships and Related Party Transactions – Other Financings.” |

<div align='center'>11</div>

| Risk factors            |     | Investing in our securities involves a high degree of risk. You should read the “Risk Factors” starting on page 14 of this prospectus for a discussion of factors to consider carefully before deciding to invest in our Ordinary Shares. |
| NYSE                    
 American trading symbol |     | We have applied to list                                                                                                                                                                                                                   
 our Ordinary Shares on the NYSE American under the symbol “RGNT”. This offering is contingent upon the Ordinary Shares                                                                                                                    
 being listed on the NYSE American, and no assurance can be given that our application will be approved or that a trading market will                                                                                                      
 develop.                                                                                                                                                                                                                                  |

The number of the Ordinary Shares to be issued and outstanding immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby are sold, and is based on 3,929,378 Ordinary Shares issued and outstanding as of the date of this prospectus. This number excludes:

| ● | 79,290 Ordinary Shares issuable upon the exercise of options to consultants under our incentive option plan outstanding